AI Article Synopsis
- Denosumab is used to treat unresectable giant cell tumors of bone (GCTB) and may help before surgery, but guidelines for its use in en bloc resection are lacking.
- A 26-year-old patient with GCTB experienced significant pain relief and tumor changes after receiving 3 months of neoadjuvant denosumab before surgery.
- Post-surgery, the patient showed no signs of tumor recurrence and returned to normal function, indicating that neoadjuvant denosumab can be beneficial in managing GCTB symptoms and improving surgical outcomes.
Article Abstract
Introduction: The RANK ligand inhibitor denosumab has been used to treat cases of unresectable giant cell tumors of bone (GCTB) or preoperatively to facilitate intralesional curettage. However, there are no clear guidelines for use of denosumab prior to en bloc resection.
Case Presentation: In this study, a 26-year-old patient presented with atraumatic lateral knee pain. X-rays demonstrated a destructive lesion within the proximal fibula, and biopsy confirmed the diagnosis of GCTB.
Management And Outcomes: The patient received 3 months of neoadjuvant denosumab with complete resolution of his pain and cortical rim formation surrounding the tumor. The tumor was removed en bloc with negative margins. At 6-month follow-up, the patient had returned to his functional baseline with no evidence of tumor recurrence.
Conclusion: Neoadjuvant denosumab can mitigate symptoms related to GCTB and promotes cortical bone formation, facilitating en bloc resection and permitting acceptable functional outcomes in select cases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235432 | PMC |
| http://dx.doi.org/10.52965/001c.35457 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!